Fluzone ( DrugBank: - )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 21 | ミトコンドリア病 | 1 |
| 49 | 全身性エリテマトーデス | 1 |
21. ミトコンドリア病
臨床試験数 : 39 / 薬物数 : 42 - (DrugBank : 32) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01831934 (ClinicalTrials.gov) | September 2010 | 19/3/2013 | Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS) | Metabolic and Immune Responses to TIV in Patients With Mitochondrial Disease | MELAS Syndrome | Biological: Fluzone® | Stanford University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | 13 Years | 65 Years | All | 22 | Phase 4 | United States |
49. 全身性エリテマトーデス
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00611611 (ClinicalTrials.gov) | October 2007 | 28/1/2008 | BLYS and IFN in SLE | BLyS and IFN Responses to Antigen Challenge in Human SLE | Systemic Lupus Erythematosus | Biological: fluzone;Biological: pneumovax | University of Alabama at Birmingham | Hospital for Special Surgery, New York | Completed | 19 Years | 65 Years | Both | 39 | N/A | United States |